Bevacizumab (Avastin) eye drops inhibit corneal neovascularization

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 2, 2008, Pages 281-284

  Bock, Felix ^a   König, Yanyan ^a   Kruse, Friedrich ^a   Baier, Martin ^a   Cursiefen, Claus ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Angiogenesis; Bevacizumab; Cornea; Eye drops; Inhibition

Indexed keywords

BEVACIZUMAB; EYE DROPS;

ADULT; AGED; ARTICLE; CHEMICAL BURN; CLINICAL ARTICLE; CLINICAL PROTOCOL; CORNEA NEOVASCULARIZATION; CORNEA PERFORATION; DRUG ACTIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; INHIBITION KINETICS; KERATOCONUS; LIMBAL STEM CELL TRANSPLANTATION; MALE; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; SKIN DEFECT; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CORNEAL NEOVASCULARIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38549107051     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-007-0684-4     Document Type: Article

References (11)

1. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ (2006) Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142:162-164
2. Bock F, Onderka J, Dietrich T, Dietrich T, Bachmann B, Kruse FE, Cursiefen C (2007) Bevacizumab is a potent inhibitor of inflammatory angiogenesis and lymphangiogenesis in the cornea. Invest Ophthalmol Vis Sci 48:2545-2552
3. Bock F, König Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C (2007) Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104:336-344
4. Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242-249
5. Cursiefen C, Rummelt C, K̈chle M (2000) Immunohistochemical localization of VEGF, TGFα and TGFβ 1 in human corneas with neovascularization. Cornea 19:526-533
6. Cursiefen C, Rummelt C, Küchle M, Schlötzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87:101-106
7. Cursiefen C, Maruyama K, Liu Y, Chen L, Jackson D, Wiegand S, Dana MR, Streilein JW (2004) Inhibition of hem- and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45:2666-2673
8. Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Streilein JW, Dana MR (2006) Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 103:11405-11410
9. Manzano R, Peyman G, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chevez-Barrios P (2007) Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 91:804-807
10. Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577-1579
11. Kuhlmann A, Amann K, Schlötzer-Schrehardt U, Kruse FE, Cursiefen C (2005) Endothelin-1 and Eta/Etb-receptor protein and mRNA expression in normal and vascularized human corneas. Cornea 24:837-844